Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective To present a case series of ipilimumab-related secondary adrenal insufficiency. Methods In this cases series, we review the presentation, evaluation, diagnosis, and management of patients with advanced melanoma who received ipilimumab and were referred to our endocrinology clinic for evaluation of hormonal abnormalities. Results Seven patients presented with symptoms, signs, or biochemical evidence of adrenal insufficiency 6 to 12 weeks after starting ipilimumab therapy. Ipilimumab is a CTLA-4 monoclonal antibody that is approved for the treatment of metastatic melanoma and has widespread use for this disease. All 7 patients had biochemical evidence of profound secondary adrenal insufficiency. Thyroid function abnormalities, central hypogonadism, and low insulinlike growth factor 1 levels were seen in a subset of patients. Only 2 patients had abnormal findings on pituitary magnetic resonance imaging. Posterior pituitary function remained normal. Conclusions Our findings suggest that the enhanced immune response associated with ipilimumab therapy may have a predilection for corticotroph and possibly thyrotroph cells. We recommend periodic hypothalamic-pituitary-adrenal axis monitoring for patients on this therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 1×
“autoimmune endocrinopathies such as Graves disease and Hashimoto thyroiditis (10,11), there have been no reports describing the association of CTLA4 polymorphisms with”
BackgroundDowney, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · cited 1×
“Interestingly, our own experience and the accumulated evidence in the literature suggest that systemic glucocorticoid administration does not alter the antitumor activity of CTLA-4 blockade (5,7-9).”
BackgroundThyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179
Self-citation
Cited by
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Self-citationEndocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0483 · Cited by 320
Albarel, F., Gaudy, C., Castinetti, F., Carré, T., Morange, I., Conte-Devolx, B., Grob, J.-J., & Brue, T. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0845 · Cited by 289
Min, L., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Luke, J. J., Donahue, H., Davis, M., Carroll, R. S., & Kaiser, U. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2353 · Cited by 274
Self-citationTan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT
Bacanovic, S., Burger, I. A., Stolzmann, P., Hafner, J., & Huellner, M. W. (2015) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000887 · Cited by 82
Adrenal Insufficiency in Adults: A Review
Vaidya, A., Findling, J., & Bancos, I. (2025) · JAMA · doi:10.1001/jama.2025.5485 · Cited by 75
Self-citationIpilimumab‐induced hypophysitis in melanoma patients: an Australian case series
Lam, T., Chan, M. M. K., Sweeting, A. N., De Sousa, S. M. C., Clements, A., Carlino, M. S., Long, G. V., Tonks, K., Chua, E., Kefford, R. F., et al. (2015) · Internal Medicine Journal · doi:10.1111/imj.12819 · Cited by 37
Metadata
- Authors
- Min, L., Vaidya, A., & Becker, C.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 18
- Issue
- 3
- Pages
- 351-355
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2017347750
- Cited by
- 63
- References
- 3
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.